Irinotecan/sorafenib

Irinotecan/sorafenib Reactions 1680, p194 - 2 Dec 2017 Diarrhoea: case report A 19-year-old man developed significant diarrhoea while receiving sorafenib and irinotecan for unresponsive renal masses [routes, dosages, duration of treatments to reaction onset and outcome not stated]. He subsequently died secondary to multisystem failure. The man was hospitalised because of a renal neoplasm. Following examinations, he underwent a radical tumour nephrectomy. After further examination, a diagnosis of TFE-3 translocation-associated renal cell carcinoma was made. He was initially treated with AREN0321 chemotherapy regimen for high risk renal tumours comprised cyclophosphamide, doxorubicin, vincristine and carboplatin, along with palliative radiation therapy but he developed disease progression. Consequently, the regimen was changed to COG protocol involving vincristine and irinotecan but no significant response was obtained. Hence, He started receiving a combination regimen of sorafenib and irinotecan which resulted in stable disease for nearly 8 weeks, but he experienced significant diarrhea. The man was advised to discontinue sorafenib and the treatment was changed to a combination of irinotecan, temsirolimus, and bevacizumab. Although, PET scan was negative, clinically progressive disease was developed under treatment and he died secondary to multisystem failure. Author comment: "It was decided to start the patient on a combination regimen consisting of Sorafenib plus Irinotecan. This combination resulted in stable disease for approximately 8 weeks. However, this combination caused significant diarrh[o]ea, and Sorafenib was stopped." Nelius T, et al. TFE3 translocation-associated renal cell carcinoma presenting as avascular necrosis of the femur in a 19-year-old patient: Case report and review of the literature. Case Reports in Medicine 2011: 14 Jul 2011. Available from: URL: http://doi.org/10.1155/2011/432917 - USA 803283898 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Irinotecan/sorafenib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/irinotecan-sorafenib-EvfzPZ89U0
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39125-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p194 - 2 Dec 2017 Diarrhoea: case report A 19-year-old man developed significant diarrhoea while receiving sorafenib and irinotecan for unresponsive renal masses [routes, dosages, duration of treatments to reaction onset and outcome not stated]. He subsequently died secondary to multisystem failure. The man was hospitalised because of a renal neoplasm. Following examinations, he underwent a radical tumour nephrectomy. After further examination, a diagnosis of TFE-3 translocation-associated renal cell carcinoma was made. He was initially treated with AREN0321 chemotherapy regimen for high risk renal tumours comprised cyclophosphamide, doxorubicin, vincristine and carboplatin, along with palliative radiation therapy but he developed disease progression. Consequently, the regimen was changed to COG protocol involving vincristine and irinotecan but no significant response was obtained. Hence, He started receiving a combination regimen of sorafenib and irinotecan which resulted in stable disease for nearly 8 weeks, but he experienced significant diarrhea. The man was advised to discontinue sorafenib and the treatment was changed to a combination of irinotecan, temsirolimus, and bevacizumab. Although, PET scan was negative, clinically progressive disease was developed under treatment and he died secondary to multisystem failure. Author comment: "It was decided to start the patient on a combination regimen consisting of Sorafenib plus Irinotecan. This combination resulted in stable disease for approximately 8 weeks. However, this combination caused significant diarrh[o]ea, and Sorafenib was stopped." Nelius T, et al. TFE3 translocation-associated renal cell carcinoma presenting as avascular necrosis of the femur in a 19-year-old patient: Case report and review of the literature. Case Reports in Medicine 2011: 14 Jul 2011. Available from: URL: http://doi.org/10.1155/2011/432917 - USA 803283898 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial